Pan Yujin, Li Deyu, Yang Jiuhui, Wang Ning, Xiao Erwei, Tao Lianyuan, Ding Xiangming, Sun Peichun, Li Dongxiao
Department of Hepatobiliary Pancreatic Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
Zhengzhou Key Laboratory of Minimally Invasive Treatment for Liver Cancer, Henan Provincial People's Hospital, Zhengzhou, China.
Front Oncol. 2021 Oct 28;11:757307. doi: 10.3389/fonc.2021.757307. eCollection 2021.
Much importance is attached to the clinical application value of circulating tumor cells (CTCs), meanwhile tumor-proximal CTCs detection has interested researchers for its unique advantage. This research mainly discusses the correlation of portal venous (PoV) CTCs counts in different epithelial-mesenchymal transition status with clinicopathologic parameters and postoperative prognosis in resectable pancreatic ductal adenocarcinoma patients (PDAC).
PDAC patients (n=60) who received radical resection were enrolled in this research. PoV samples from all patients and peripheral venous (PV) samples from 32 patients among them were collected to verify spatial heterogeneity of CTCs distribution, and explore their correlation with clinicopathologic parameters and clinical prognosis.
CTCs detectable rate and each phenotype count of PoV were higher than those of PV. Patients with recurrence had higher PV and PoV epithelial CTCs (E-CTCs) counts than recurrence-free patients (<0.05). Some unfavourable clinicopathologic parameters were closely related to higher PoV CTCs counts. Multivariate regression analysis demonstrated that PoV mesenchymal CTC (M-CTC)s≥1/5 ml was an independent risk factor for metastasis free survival (MFS) (=0.003) and overall survival (OS) (=0.043).
Our research demonstrated that portal venous was a preferable vessel for CTC test, and patients with PoV M-CTC≥1/5 ml had shorter MFS and OS time in resectable PDAC patients. PoV CTC phenotype detection has the potential to be a reliable and accurate tool to identify resectable PDAC patients with high tendency of postoperative metastasis for better stratified management.
循环肿瘤细胞(CTCs)的临床应用价值备受重视,同时肿瘤近端CTCs检测因其独特优势引起了研究人员的兴趣。本研究主要探讨可切除性胰腺导管腺癌(PDAC)患者不同上皮-间质转化状态下门静脉(PoV)CTCs计数与临床病理参数及术后预后的相关性。
本研究纳入60例接受根治性切除术的PDAC患者。收集所有患者的PoV样本以及其中32例患者的外周静脉(PV)样本,以验证CTCs分布的空间异质性,并探讨其与临床病理参数及临床预后的相关性。
PoV的CTCs可检测率及各表型计数均高于PV。复发患者的PV和PoV上皮CTCs(E-CTCs)计数高于无复发患者(<0.05)。一些不良临床病理参数与较高的PoV CTCs计数密切相关。多因素回归分析表明,PoV间质CTCs(M-CTCs)≥1/5 ml是无转移生存期(MFS)(=0.003)和总生存期(OS)(=0.043)的独立危险因素。
我们的研究表明门静脉是CTCs检测的理想血管,在可切除性PDAC患者中,PoV M-CTCs≥1/5 ml的患者MFS和OS时间较短。PoV CTC表型检测有可能成为一种可靠且准确的工具,用于识别术后转移倾向高的可切除性PDAC患者,以实现更好的分层管理。